Get the Daily Brief
Latest Biotech News
Keep neutrophils in night mode: ATI2341 reduces post‑MI inflammation in models
A team from CNIC and Yale reported in Journal of Experimental Medicine that neutrophils follow a circadian program that alters their aggressiveness, making nighttime neutrophils less damaging...
Child dies after experimental brain gene therapy — field confronts safety alarm
A young child died two and a half days after receiving an experimental viral vector designed to deliver genes deep into the brain, according to a STAT+ report. The patient had been treated with a...
Sobi to buy Arthrosi for $950M upfront — gout pipeline deal locks in late‑stage asset
Swedish drugmaker Sobi agreed to acquire Arthrosi Therapeutics, paying $950 million upfront plus up to $550 million in milestone payments, the company announced. Arthrosi’s lead candidate is a...
Structure’s oral GLP‑1 posts double‑digit weight loss — shares surge after Phase II readout
Structure Therapeutics reported positive Phase II data for aleniglipron, an oral, biased GPCR agonist for obesity, showing a placebo‑adjusted mean weight loss in the low double digits at 36 weeks...
FDA clears Milestone’s nasal arrhythmia spray — Cardamyst approved after two rejections
The FDA approved Milestone Pharmaceuticals’ nasally delivered emergency treatment Cardamyst (etripamil) for a form of cardiac arrhythmia, the company confirmed. Cardamyst had been turned down...
Laguna Bio advances engineered Listeria living drug — pediatric leukemia trial planned
Laguna Bio is advancing a living‑therapeutic approach that uses a highly attenuated Listeria monocytogenes strain engineered to activate multifactorial immune responses, the founders told...
AI and physics model find Parkinson’s candidate — Gain Therapeutics announces mechanism‑based lead
Gain Therapeutics disclosed a drug discovered through an AI plus physics‑based modeling platform that allosterically binds a dysfunctional enzyme, restores its function, and reduces...
Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 — Nature Communications report
Researchers reported new human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin, according to a Nature Communications paper. The antibodies show broad binding and...
Targeting ALKBH5 halts colorectal cancer stemness and resistance — Nature Communications discovery
A Nature Communications paper revealed that inhibiting the m6A RNA demethylase ALKBH5 suppresses colorectal cancer stemness and reverses chemoresistance in preclinical models. The study links...
LRBA inhibition degrades CTLA‑4 — new route to boost cancer immunity
A Nature Communications study found that targeting LRBA (lipopolysaccharide‑responsive and beige‑like anchor protein) promotes degradation of the immune checkpoint CTLA‑4 and enhances anti‑tumor...
China issues organoid guidelines — regulatory and ethical framework released
China published guidance on human organoid research, offering regulatory and bioethical direction for organoid generation, use, and oversight, the analysis reported. The guidelines address...
Sobi to buy Arthrosi: $950M upfront for Phase‑3 gout play
Sobi announced an acquisition agreement to buy Arthrosi Therapeutics, paying $950 million upfront with up to $550 million in contingent milestones. The deal brings a Phase 3 gout candidate into...
Structure’s oral GLP‑1 shocks investors – stock doubles after Phase II
Structure Therapeutics reported positive Phase II ACCESS results for aleniglipron, an oral GLP‑1 candidate, and shares surged more than 100% on the data. The mid‑stage readout showed clinically...
FDA clears Cardamyst: nasal arrhythmia spray approved after prior rejections
The FDA approved Milestone Pharmaceuticals’ nasally administered emergency treatment Cardamyst (etripamil) for a form of acute arrhythmia, after the drug was previously denied twice. The clearance...
Laguna Bio bets engineered Listeria on pediatric leukemia: living drug approach
Laguna Bio unveiled a microbial immunotherapy program that engineers an attenuated Listeria monocytogenes strain to stimulate multifactorial immune responses against cancer. Founders Jonathan...
New human antibodies neutralize clade 2.3.4.4b H5N1: potential pandemic countermeasure
Researchers led by Alzua and colleagues reported a panel of human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin. Published in Nature Communications, the work...
SARS‑CoV‑2 nucleocapsid XEC mutation linked to more severe disease
A Nature Communications study by Tsujino, Tsuda, Deguchi and colleagues identified an XEC mutation in the SARS‑CoV‑2 nucleocapsid that increases viral pathogenicity independent of spike changes....
AI plus physics modeling surfaces a Parkinson’s drug candidate at Gain Therapeutics
Gain Therapeutics used an AI and physics‑based modeling platform to identify a novel small molecule that allosterically binds a dysfunctional enzyme, restores its activity, and reduces...
GLP‑1 agonist shows benefit in large‑vessel occlusion stroke trial
A phase 2 randomized trial published in Nature Communications led by Wang, Ko and Leung evaluated GLP‑1 receptor agonists in patients with large‑vessel occlusion (LVO) stroke undergoing...
Targeting ALKBH5 halts colorectal cancer stemness and chemoresistance
A Nature Communications study demonstrated that inhibiting the m6A RNA demethylase ALKBH5 suppresses colorectal cancer stemness and reverses chemoresistance. The authors linked ALKBH5 activity to...